News Search Results
Apr 21, 2026, 09:05 ET Insilico Medicine Announces Industry's First Longevity Board to Accelerate AI-Driven Aging Research for Drug Discovery
April 21, 2026 /PRNewswire/ -- Insilico Medicine ("Insilico", 3696.HK), a clinical-stage generative artificial intelligence (AI)-driven biotechnology company, today announced the strategic formation of the industry's first Longevity Board (Board). The initiative provides scientific oversight and
More news about: Insilico Medicine
Apr 21, 2026, 08:46 ET BiomEdit Secures Foundational Patents for Engineered Probiotic Platform Positioned to Redefine Animal Health
GREENFIELD, Ind., April 21, 2026 /PRNewswire/ -- BiomEdit, an animal health biotechnology company, today announced the issuance of foundational patents covering its engineered probiotic delivery platform. These patents support and directly
More news about: BiomEdit
Apr 21, 2026, 08:30 ET HKeybio Launches World's First NHP Hidradenitis Suppurativa Model with High Clinical Consistency to Tackle Global Drug R&D Bottleneck
NHP centers in Guangxi and Suzhou, and a state-of-the-art analysis center and rodent facility in Suzhou, serving over 1000 pharmaceutical and biotechnology clients, HKeybio is committed to providing the global biopharmaceutical industry with the most clinically relevant disease models.Through
More news about: HKeyBio
Apr 21, 2026, 08:03 ET USPTO Allows Antibody Genus Claims in Patent Enabled by Integral Molecular's Paratope-PLUS™ CDR-Scanning
genera using structure-based claims supported by comprehensive experimental data, based on Integral Molecular's 2025 publication in Nature Biotechnology2. The allowance comes in the wake of the 2023 U.S. Supreme Court ruling in Amgen Inc. v. Sanofi, which emphasized that genus claims must be
More news about: Integral Molecular
Apr 21, 2026, 08:00 ET Pulmatrix Announces Closing of Preferred Stock Transaction as Part of Planned Merger
https://www.pulmatrix.com/pipeline.html.About Eos SENOLYTIX, Inc.Eos SENOLYTIX is a biotechnology company focused on developing first-in-class gerotherapeutic peptide medicines that target the underlying biological mechanisms of aging. Eos's
More news about: Pulmatrix Inc.
Apr 21, 2026, 08:00 ET Celltrion to present seven abstracts in inflammatory bowel disease (IBD) at 2026 Digestive Disease Week® (DDW)
well as the novel biologic ZYMFENTRA® (infliximab-dyyb).Celltrion USA will continue to leverage Celltrion's unique heritage in biotechnology, supply chain excellence and best-in-class sales capabilities to improve access to high-quality biopharmaceuticals for U.S. patients. For more information,
More news about: Celltrion
Apr 21, 2026, 06:30 ET Flagship Pioneering Launches Serif Biomedicines to Establish Modified DNA as a New Biotechnology
Flagship Pioneering, a scientific innovation engine for transformative platforms and products, today announced the launch of Serif Biomedicines, a biotechnology company pioneering Modified DNA as a new class of medicines. Modified DNA brings together the best features of mRNA and gene therapy, while mitigating
More news about: Flagship Pioneering
Apr 21, 2026, 06:00 ET Danaher Reports First Quarter 2026 Results
D Impairment charges related to a facility in the Biotechnology segment recorded in the three-month period ended March 28, 2025 ($15 million pretax as reported in this line item, $11 million after-tax).
More news about: Danaher Corporation
Apr 20, 2026, 22:34 ET Quality Executive Partners, Inc.® Announces Exclusive Partnership with Vi'eNnI® Training and Consulting LLP to Accelerate Workforce Development in India's Huge Pharmaceutical Sector with Virtuosi®
sustainable compliance. Known for its practical, implementation-focused approach, Vi'eNnI® enables pharmaceutical and biotechnology companies to translate training into measurable improvements on the shop floor, supporting continuous improvement and long-term capability development
More news about: Quality Executive Partners, Inc.
Apr 20, 2026, 16:01 ET Nektar Therapeutics Announces Proposed Public Offering
SAN FRANCISCO, April 20, 2026 /PRNewswire/ -- Nektar Therapeutics (Nasdaq: NKTR), a clinical-stage biotechnology company focused on the development of innovative medicines in the field of immunotherapy, today announced that it has commenced an underwritten
More news about: Nektar Therapeutics
Apr 20, 2026, 15:36 ET AdvisorShares Applauds Executive Order Accelerating Access to Psychedelic Therapies
significant business activities in, or significant exposure to, the psychedelics industry including producers or distributors of psychedelic medicines, biotechnology companies engaged in research and development of psychedelic medicines, and companies that are part of the supply chain for psychedelics. Psychedelics
More news about: AdvisorShares
Apr 20, 2026, 10:00 ET AACR 2026 Oral Presentation: Abogen Presents Preliminary Results of ABO2203 (mRNA-Encoded CD3×CD19 TCE) from First-in-Human Clinical Study in R/R B-NHL
SAN DIEGO, April 20, 2026 /PRNewswire/ -- Abogen, a clinical-stage biotechnology company focused on RNA innovation, today announced preliminary clinical results from the first-in-human (FIH) study of ABO2203 in patients with
More news about: Abogen
Apr 20, 2026, 10:00 ET AACR 2026 Oral Presentation: Abogen Presents Preliminary Results of ABO2203 (mRNA-Encoded CD3×CD19 TCE) from First-in-Human Clinical Study in R/R B-NHL
SAN DIEGO, April 20, 2026 /PRNewswire/ -- Abogen, a clinical-stage biotechnology company focused on RNA innovation, today announced preliminary clinical results from the first-in-human (FIH) study of ABO2203 in patients with
More news about: Abogen
Apr 20, 2026, 09:30 ET Atlas Data Storage Selected to Present at TSMC Technology Symposium
Innovation Zone," said Siraj Nour ElAhmadi , Atlas COO. "This recognition reflects Atlas leadership in the convergence of semiconductor scaling and biotechnology. Our platform leverages advanced CMOS designs to enable the massive parallelization and controls of a molecular substrate unlocking new categories
More news about: Atlas Data Storage
Apr 20, 2026, 09:00 ET Congruence Announces Participation at the 2026 Bloom Burton & Co. Healthcare Investor Conference
MONTREAL, April 20, 2026 /PRNewswire/ -- Congruence Therapeutics, a clinical-stage, computationally-driven biotechnology company building a unique pipeline of pharmacological correctors for diseases of protein misfolding, including MC4R-deficient genetic obesity, GBA1-driven
More news about: Congruence Therapeutics
Apr 20, 2026, 09:00 ET Lilly to acquire Kelonia Therapeutics to advance in vivo CAR-T cell therapies
April 20, 2026 /PRNewswire/ -- Eli Lilly and Company (NYSE: LLY) and Kelonia Therapeutics, Inc. ("Kelonia"), a clinical-stage biotechnology company pioneering in vivo gene delivery, today announced a definitive agreement for Lilly to acquire Kelonia.Kelonia has developed
More news about: Eli Lilly and Company
Apr 20, 2026, 09:00 ET Eclipsebio Launches eCOMPASS™, an AI-Enabled Lab-in-the-Loop Platform for RNA Therapeutic Development
[email protected] EclipsebioEclipsebio is a private biotechnology company headquartered in San Diego that combines AI-powered sequence design, rapid prototyping, and sequencing-based analytics to support RNA drug
More news about: Eclipsebio
Apr 20, 2026, 08:30 ET Pinnacle Food Group Limited Announces Entry Into a Non-Binding MOU to Explore Establishing an Open Yeast Platform Hub in Hong Kong
established by Dr. Scott Pownall in 2021. The current library contains hundreds of valuable DNA assembly parts to support synthetic biology research and biotechnology in yeast. The second part is the Open Yeast Strain Bank, an open-access, growing library of yeast strains made available to researchers worldwide.
More news about: Pinnacle Food Group Limited
Apr 20, 2026, 08:00 ET Deck Bio Presents Preclinical Data on DBXO-1, a Multi-pMHC Targeted T Cell Engager, at AACR 2026
Deck Bio, a biotechnology company advancing multi-pMHC targeted T cell engagers for solid tumors, today presented new preclinical data for its lead program, DBXO-1, at the
More news about: Deck Bio, Inc.
Apr 20, 2026, 08:00 ET Sapience Therapeutics Presents First Clinical Results from Phase 2 Study of ST316, First-in-Class β-catenin Antagonist, in Second-Line Colorectal Cancer at the American Association for Cancer Research (AACR) Annual Meeting 2026
TARRYTOWN, N.Y., April 20, 2026 /PRNewswire/ -- Sapience Therapeutics, Inc., a clinical-stage biotechnology company focused on the discovery and development of peptide therapeutics to address oncogenic and immune dysregulation that drive cancer, today
More news about: Sapience Therapeutics, Inc.
Apr 20, 2026, 08:00 ET Argo Biopharma Doses First Patients in Phase II Clinical Trials of siRNA Therapy BW-40202
effectively slow disease progression and improve long-term outcomes.About Argo BiopharmaArgo Biopharma is a clinical-stage biotechnology company committed to developing next-generation RNAi therapeutics to provide better treatment options for patients worldwide. The company has established
More news about: Argo Biopharmaceutical Co., Ltd
Apr 20, 2026, 08:00 ET Adcendo ApS Provides Updates on Pipeline Progress and Recent Achievements for Its First- and Best-in-Class Antibody-Drug Conjugates
vision to deliver new treatments to cancer patients with limited options."About Adcendo ApSAdcendo ApS is a clinical-stage biotechnology company headquartered in Copenhagen, Denmark, with operations in Boston, Massachusetts. The company is developing a pipeline of first- and potential
More news about: Adcendo
Apr 20, 2026, 08:00 ET Adcendo ApS Provides Updates on Pipeline Progress and Recent Achievements for Its First- and Best-in-Class Antibody-Drug Conjugates
vision to deliver new treatments to cancer patients with limited options."About Adcendo ApSAdcendo ApS is a clinical-stage biotechnology company headquartered in Copenhagen, Denmark, with operations in Boston, Massachusetts. The company is developing a pipeline of first- and potential
More news about: Adcendo
Apr 20, 2026, 07:30 ET 52-Week Topline Results from 16-Week Blinded Treatment Extension of REZOLVE-AA Demonstrate Deepening of Responses in Severe-to-Very-Severe Alopecia Areata with Rezpegaldesleukin
SAN FRANCISCO, April 20, 2026 /PRNewswire/ -- Nektar Therapeutics (Nasdaq: NKTR), a clinical-stage biotechnology company focused on development of novel immunology therapies, today announced new results from a blinded 16-week treatment extension period in its
More news about: Nektar Therapeutics
Apr 20, 2026, 07:30 ET TJ Biopharma Enters into Agreement with Biogen for Felzartamab Assets in the Greater China Region
regulatory authority, and its safety and effectiveness have not been established.About BiogenFounded in 1978, Biogen is a leading biotechnology company that pioneers innovative science to deliver new medicines to transform patients' lives and to create value for shareholders and our communities.
More news about: TJ Biopharma